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ABSTRACT 
The value of Phosphohistone H3 as a proliferation marker for 
evaluating invasive breast cancers  
(With an emphasis on comparisons to Ki-67) 
 
Ji-Ye Kim 
 
Department of Medicine, 
The Graduate School, Yonsei University  
 
(Directed by Professor Ja Seung Koo) 
INTRODUCTION Ki-67 is a widely used marker of proliferation, but 
controversial due to problems of non-specificity and lack of 
reproducibility. In comparison, Phosphohistone H3 (PHH3) is specific 
marker for mitosis with good reproducibility. We compare the two 
markers using surgical slides of 220 breast cancer cases diagnosed from 
2012 to 2013.  
METHODS The most representative sections of invasive breast cancer 
surgical cases were immunohistochemically stained for Ki-67 and 
PHH3.  
RESULTS Ki-67 and PHH3 had a good positive correlation between 
each other. PHH3 was tested for inter-rater agreement between two 
raters using two methods. First method was assessment under a 
microscope while the second method was assessment with taken 
2 
photographs. Both demonstrated nearly perfect intra-class correlation 
coefficient (0.996, 0.977). PHH3 examined for 10HPF had a tendency 
to over-grade compared to H-E mitotic index (29 cases, evenly 
distributed). PHH3 examined at low power (objective 10x) correlated 
well with scores of 10HPF evidencing ability to accurately identify 
mitotically active areas(r = 0.999). Finally, PHH3 significantly 
correlated with recurrence-free survival (P = 0.006), while Ki-67 did 
not (P = 0.053). 
CONCLUSION The problems of Ki-67 for lack of reproducibility and 
low specificity to measure proliferation may be overcome by the use of 
PHH3 in diagnosis of breast cancer. 
 
 
 
 
 
 
 
 
 
Keywords Ki-67, PHH3, proliferation, invasive breast cancer, 
reproducibility 
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I. Introduction 
Proliferative activity is an important diagnostic criteria in breast cancers.
1
 In 
practice, proliferative activity of breast cancer is routinely evaluated through 
assessment of histological grade as the mitotic activity index (MAI), which is 
largely responsible for the prognostic value of tumor grade.
2
 Breast cancer 
classification based on molecular subtypes also depends on cancer cell 
proliferative activity, as measured by Ki-67.
3,4
 Even in commercially available 
prognostic molecular assays, such as Oncotype Dx, cancer proliferative 
activity through the use of Ki-67 is an important determinant factor.
5
 
 One of the best known ways to measure tumor proliferative activity 
is assessment of Ki-67 labeling index through immunohistochemical staining 
4 
with the MIB-1 antibody. Ki-67 has been reported to be a strong predictive 
factor in invasive ductal carcinoma without pre-operative chemotherapy 
treatment
6,7
 and used as a prognostic predictor in post-chemotherapy invasive 
ductal carcinomas. However, Ki-67 is a DNA-binding nuclear protein that is 
expressed in all actively dividing cells, except for G0 resting phase cells. 
Because Ki-67 is expressed in all non-mitotic phase cells of G1, S, and G2 
phase, it is criticized to be non-specific for proliferation.
5
  
 Limitations of Ki-67 may be overcome through the use of 
Phosphohistone H3 (PHH3). PHH3 is a specific marker of mitotic phase cells. 
Histone H3 is a nuclear core histone protein of the DNA chromatin, where it 
plays an important role in chromosome condensation and cell-cycle 
progression during cell mitosis and meiosis after phosphorylation of the 
serine-10 and serine-28 terminus. Such activating phosphorylation occurs 
during late G2 phase to early prophase, while dephosphorylation occurs 
slowly from late anaphase to early telophase of mitosis. Therefore in 
metaphase, the cell is always heavily phosphorylated, while interphase cells 
are unstained or minimally stained.
8
 
Immunodetection of phosphohistone H3 has been reported in 
multiple studies concerning various human tumors (colorectal 
adenocarcinoma, ovarian serous adenocarcinoma, pulmonary neuroendocrine 
carcinoma, uterine smooth muscle tumors, astrocytomas and meningiomas), 
5 
each highlighting its sensitive and specific role as a marker of mitotic figures 
and correlated well with outcome.
9
 In a study investigating the use of PHH3 
in breast cancer, H & E mitotic index strongly correlated with PHH3.
10
 In that 
study, the authors concluded that PHH3 can be used in breast grading because 
PHH3 allows better accuracy in detection of mitotic figures. More recently 
there has also been a report that PHH3 is a better than Ki-67 as a prognostic 
factor of breast cancer. However, these studies were conducted through TMA 
samples, not representative of the problems of tumor heterogeneity or limited 
in their number of cases (less than 100 cases).
3
 
Our study improves on the previous studies because it is conducted 
on more than 200 cases of surgical whole slides of the most representative 
tumor section. Our purpose was to compare the most commonly used 
proliferation marker, Ki-67 with PHH3 and evaluate the value of each in 
search for the most adequate marker for breast cancer proliferation activity.  
 
 
 
 
 
6 
II. Materials and Methods 
1. Patient selection and histologic evaluation 
220 tissue samples from 218 donor patients who had invasive ductal cancer, 
Not Otherwise Specified, diagnosed and surgically resected at Severance 
Hospital from January 2012 to December 2013 were analyzed. Those cases 
that had been treated with pre-operative chemotherapy or radiation therapy 
were excluded from the study. The study was approved by the Institutional 
Review Board of Yonsei University Severance Hospital. IRB exempted the 
informed consent from patients. Hematoxylin & Eosin (H&E)-stained slides 
from all cases were reviewed by a breast pathologist (Koo JS). Histological 
grade was assessed using the Nottingham grading system.
11
 Clinicopathologic 
parameters evaluated in each case included patient age at initial diagnosis, 
lymph node metastasis, tumor recurrence, distant metastasis, and patient 
survival. 
 
2. Immunohistochemistry 
Antibodies used for immunohistochemistry are listed in Table 1. All 
immunohistochemistry was performed with formalin-fixed, paraffin-
embedded tissue sections. The most representative section of the tumor was 
selected for immunohistochemial staining. Briefly, 5-μm-thick sections were 
7 
obtained with a microtome, transferred onto adhesive slides, and dried at 62°C 
for 30 minutes. After incubation with primary antibodies, immunodetection 
was performed with biotinylated anti-mouse immunoglobulin, followed by 
peroxidase-labeled streptavidin using a labeled streptavidin biotin kit with 
3,3′-diaminobenzidine chromogen as the substrate. The primary antibody 
incubation step was omitted in the negative control. Positive control tissue 
was used as per the manufacturer’s recommendation. Slides were 
counterstained with Harris hematoxylin. 
 
Table 1. Antibody sources, clones, and dilutions 
Antibody  Clone Dilution Vendor 
ER SP1 1:100 Thermo Scientific, CA, USA 
PR PgR 1:50 DAKO, Glostrup, Denmark 
HER-2 Polyclonal 1:1500 DAKO, Glostrup, Denmark 
Ki-67 MIB1 1:100 DAKO, Glostrup, Denmark 
PHH3 Polyclonal  1:100 Cell Marque, Rocklin, CA, USA 
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3. Interpretation of immunohistochemical staining 
All immunohistochemical markers were accessed by light microscopy. A cut-
off value of 1% or more positively stained nuclei was used to define ER and 
PR positivity.
12
 HER-2 staining was analyzed according to the American 
Society of Clinical Oncology (ASCO)/College of American Pathologists 
(CAP) guidelines using the following categories: 0 = no immunostaining; 1+ 
= weak incomplete membranous staining, less than 10% of tumor cells; 2+ = 
complete membranous staining, either uniform or weak in at least 10% of 
tumor cells; and 3+ = uniform intense membranous staining in at least 30% of 
tumor cells.
13
 HER-2 immunostaining was considered positive when strong 
(3+) membranous staining was observed, whereas cases with 0 to 1+ were 
regarded as negative. Cases showing 2+ HER-2 expression were evaluated for 
HER-2 amplification by fluorescent in situ hybridization (FISH). 
Scoring method for Ki-67 and PHH3 was as follows. After scanning 
the tumor area at low power field, four HPFs (objective 40x) that best 
represents the overall tumor were selected from the invasive front of the 
tumor. When hot spots were present, these were included for the overall 
average score. Each field of examination was photographed in order to assure 
consistency of the field of examination at one time. Then cells were counted 
manually using the counter application provided by the publicly available 
image analysis program, Image J. The same tumor area on each stain was 
assessed in order to eliminate the influence of intratumoral heterogeneity. 
9 
Tumor cells were considered positive if there was any nuclear signal above 
background. Consistent with previous studies,
14,15
 intact nuclei with fine 
granular staining of phosphohistone H3 were not counted as these cells are not 
in G2 phase. Ki-67 counted for all positively nuclear stained tumor cells. A 
score was generated by dividing the number of positively stained cells by the 
total number of cells counted. A final score was taken from the average of 
four fields.  
 
4. Tumor phenotype classification 
In this study, we classified breast cancer phenotypes according to the 
immunohistochemistry results for ER, PR, HER-2, Ki-67 and FISH results for 
HER-2 as follows:
16
 luminal A type, ER or/and PR positive, HER-2 negative 
and Ki-67 LI < 14%; Luminal B type, (HER-2 negative) ER or/and PR 
positive, HER-2 negative and Ki-67 LI. ≥ 14%; (HER-2 positive) ER or/and 
PR positive and HER-2 overexpressed or/and amplified; HER-2 
overexpression type, ER and PR negative and HER-2 overexpressed or/and 
amplified; TNBC type: ER, PR, and HER-2 negative.  
 
 
10 
5. Inter-rater agreement 
For inter-rater agreement, two different methods were assessed. The first 
method involved a total of 31 PHH3 slides selected in random. These were 
scored for 10 HPF by two separate raters by individual counting of positive 
cells under a microscope. Both raters used a web-based counter application 
while scoring the glass slide under a microscope. A second method involved a 
total of 220 randomly selected PHH3 photographs and assessed separately by 
two raters.  
 
6.  Statistical analysis 
Data were analyzed using SPSS for Windows, Version 12.0 (SPSS Inc., 
Chicago, IL, USA). For determination of statistical significance, Student’s t 
and Fisher’s exact tests were used for continuous and categorical variables, 
respectively. In the case of analyzing data with multiple comparisons, a 
corrected p-value with the application of the Bonferroni multiple comparison 
procedure was used. Correlation between Ki-67 and PHH3 score was 
analyzed through linear regression and Spearman correlation coefficient. For 
inter-rater agreement, intra-class correlation coefficient and κ statistics were 
used. For comparison of dichotomous labelling indices for Ki-67 and 
phosphohistone H3 with recurrence, an optimal cut-off point was determined 
11 
by the use of ROC curves and Youden’s index. Ki-67 and PHH3 scores were 
calculated as both continuous variable and categorical variables. Statistical 
significance was set to P < 0.05. Kaplan-Meier survival curves and log-rank 
statistics were employed to evaluate time to tumor recurrence and overall 
survival. Multivariate regression analysis was performed using the Cox 
proportional hazards model. 
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III. Results 
1. Baseline characteristics of breast cancer 
Clinicopathologic characteristics of patients are summarized in Table 2. Of the 
220 breast cancer cases evaluated, 218 patients were involved. Median follow 
up was 31 months (range, 1-93months). During follow up, there were no 
deaths with 8 local recurrence/metastases.  
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Table 2. Clinicopathologic characteristics of patients 
Parameters 
Total 
N= 220 
(%) 
Ki-67 LI PHH3 PHH3/Ki-67 ratio 
Mean  
(%) ± 
SD 
P 
 
Mean 
(%) ± 
SD 
P 
Mean ± 
SD 
P 
Age (years)   0.742  0.883  0.661 
≤50 89 (40.5) 
25.3±
18.2 
 
0.38±
0.51 
 
0.0136±
0.0176 
 
>50 131 (59.5) 
26.2±
20.1 
 
0.37±
0.48 
 
0.0149±
0.0253 
 
Nuclear grade   0.074  0.212  0.910 
1 18 (8.2) 
26.0±
18.3 
 
0.44±
0.65 
 
0.0135±
0.0191 
 
2 143 (65) 
23.8±
18.7 
 
0.33±
0.44 
 
0.0149±
0.0256 
 
3 59 (26.8) 
30.6±
20.5 
 
0.46±
0.54 
 
0.0135±
0.0137 
 
Histologic 
grade 
  0.009  0.133  0.636 
I 62 (28.2) 
25.81
±20.4 
 
0.31±
0.47 
 
0.0126±
0.0242 
 
II 102 (46.4) 
22.32
±17.0 
 
0.36±
0.46 
 
0.0159±
0.0253 
 
III 56 (25.4) 
32.15
±20.6 
 
0.48±
0.55 
 
0.0136±
0.0134 
 
Tumor stage   0.694  0.802  0.670 
T1 150 (68.2) 
26.38
±20.1 
 
0.37±
0.48 
 
0.0136±
0.0200 
 
T2 66 (30) 
24.26
±16.9 
 
0.38±
0.49 
 
0.0164±
0.0277 
 
T3 4 (1.8) 
29.90
±29.4 
 
0.53±
0.85 
 
0.0104±
0.0173 
 
Nodal 
metastasis 
  0.671  0.466  0.219 
      (continued) 
        
14 
 
Parameters 
Total 
N= 220 
(%) 
Ki-67 LI PHH3 PHH3/Ki-67 ratio 
Mean  
(%) ± 
SD 
P 
 
Mean 
(%) ± 
SD 
P 
Mean ± 
SD 
P 
Absent 168 (76.4) 
26.11
±19.3 
 
0.36±
0.45 
 
0.0132±
0.0205 
 
Present 52 (23.6) 
24.81
±19.4 
 
0.42±
0.60 
 
0.0183±
0.0277 
 
Estrogen 
receptor 
  0.009  0.095  0.966 
Negative 48 (21.8) 
32.23
±21.4 
 
0.48±
0.56 
 
0.0145±
0.0177 
 
Positive 172 (78.2) 
24.01
±18.3 
 
0.34±
0.46 
 
0.0144±
0.0237 
 
Progesterone 
receptor 
  0.167  0.624  0.289 
Negative 106 (48.2) 
27.67
±19.5 
 
0.39±
0.47 
 
0.0127±
0.0147 
 
Positive 114 (51.8) 
24.07
±19.0 
 
0.36±
0.51 
 
0.0159±
0.0279 
 
HER-2 status   0.108  0.234  0.975 
Negative 186 (84.5) 
24.91
±19.2 
 
0.36±
0.48 
 
0.0144±
0.0237 
 
Positive 34 (15.5) 
30.70
±19.2 
 
0.47±
0.53 
 
0.0143±
0.0144 
 
Molecular 
subtype 
  0.075  0.102  0.673 
Luminal A 105 (47.7) 
23.99
±20.3 
 
0.29±
0.43 
 
0.0130±
0.0242 
 
Luminal B 67 (30.5) 
24.06
±14.9 
 
0.43±
0.51 
 
0.0165±
0.0229 
 
HER-2 12 (5.5) 
33.54
±19.2 
 
0.42±
0.53 
 
0.0159±
0.0194 
 
TNBC 36 (16.3) 
31.79
±22.4 
 
0.50±
0.58 
 
0.0102±
0.0105 
 
15 
2. Ki-67 was more frequently stained in tumor cells than PHH3 
PHH3 was stained for a significantly lower percentage than Ki-67 LI overall. 
The mean for PHH3 was 0.3763 while Ki-67 was 25.81 (Table 3), while the 
range for Ki-67 was wide, varying from 0 to 89. In comparison, PHH3 range 
was much narrow, ranging from 0 to 2.22. While Ki-67 stained in a variety of 
intensities and in other extraneous cells, other than tumor cells, PHH3 stained 
in only a few, in strong intensities (Figure 1). At low power, it was easy to 
distinguish areas of high mitosis and therefore count in those areas of 
maximum mitosis.  
Table 3. Basic analytical comparison between Ki-67 LI and PHH3 
Parameters Mean Range Standard Deviation 
Ki-67 25.81 0-89 19.29 
PHH3 0.3763 0.00-2.22 0.49 
 
 
 
 
  
16 
 
 
 
 
Figure 1. Ki-67 stained in various intensities (A) while the same area for 
PHH3 stained a few specific mitotically active tumor cells (B). 
 
 
 
 
 
  
A B 
17 
3. PHH3 and Ki-67 LI had a positive linear correlation 
There was a tendency for highly stained Ki-67 LI cases to be also relatively 
high in PHH3 staining. On Pearson’s correlation, r = 0.504 (P < 0.001), 
demonstrates a clear positive relationship between the two (Figure 2).  
 
Figure 2. Positive correlation between Ki-67 LI and PHH3 stain percentage, 
correlation coefficient, r = 0.504 ( P < 0.001). 
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 4. PHH3 had inter-rater agreement between raters using two different 
methods 
Two different methods were used to assess agreement for PHH3 rating. First 
method involved 31 randomly selected cases, in which PHH3 evaluated 
through the microscope and counted for ten consecutive high power fields 
between two raters (Table 4 and Figure 3A, κ = 0.331). To avoid variations by 
assessment in varied microscopic fields and evaluate the variation in threshold 
of immunointensity interpreted as positive by different pathologists, the 
second method involved 220 randomly selected cases of photographs taken at 
HPF. These were rated between two raters (Table 4 and Figure 3B). Results 
for both methods yielded significant κ values (P < 0.001) with the method 
scored with photographs having a much higher agreement than the method 
scored through the microscope (κ, 0.331 < 0.711). The intra-class correlation 
coefficient (ICC) was also assessed in consideration of the ordinal, continuous 
nature of values. ICC showed a nearly perfect agreement for both methods of 
microscope (ICC 0.996, 95% CI: 0.991-0.998) and photographs (ICC 0.977, 
95% CI: 0.970-0.982). 
 
 
 
19 
Figure 3. Scatter plot demonstrating agreement between two raters for PHH3. 
(A) 31 PHH3 stained slides evaluated under the microscope by two 
independent raters show a positive correlation, r = 0.992 (P < 0.001). (B) 220 
PHH3 photographed cases were evaluated by two independent raters show a 
positive correlation r = 0.963 (P < 0.001).  
 
Table 4. Inter-rater agreement for PHH3 and Ki-67 
 
ICC 95% CI κ P 
Microscope 0.996 0.991 0.998 0.331 < 0.001 
Photograph 0.977 0.97 0.982 0.711 < 0.001 
 
 
 
20 
5. Breast cancer cases reclassified under Nottingham’s criteria for M 
grade 
PHH3-immunostained MFs were counted based on the number of mitotic 
figures per 10 contiguous high power fields (HPF) in the area of highest 
mitotic activity, the same way as in hematoxylin and eosin- stained sections. 
Anti-PHH3-labeled MFs were easily seen and permitted quick identification 
of the areas of highest mitotic activity. PHH3 counting yielded greater 
sensitivity and in total of 46 cases suggested a change in grade. Cases which 
were downgraded from PHH3 counting were 17 cases, predominantly from 
older blocks, suggesting a loss of antigen preservation. Cases which were 
upgraded from PHH3 counting were 29 cases, which were evenly distributed 
amongst the years, thereby prove to yield greater sensitivity for detecting 
mitosis. 
 
Table 5. PHH3 counted in 10 HPF and re-classified according to M grade 
Parameters Number of cases Percent (%) 
under-graded 16 7.2 
over-graded 29 13.0 
concordance 175 78.5 
Total 220 98.7 
 
21 
6. PHH3 permitted quick identification of the areas of highest mitotic 
activity 
In order to demonstrate the efficacy of PHH3 in identifying areas of 
mitotically active hot spots in heterogeneous tumors, PHH3 labeled mitotic 
figures were counted at low power (objective 10x) and compared with counts 
on ten high power fields.  The correlation between PHH3 mitotic index (MI) 
and PHH3 MI at lower power was high (correlation coefficient, r = 0.999; 
regression coefficient R
2
 = 0.999; P = 0.001). Because there was no change in 
M grade through both methods of counting, κ statistics reveals a perfect fit of 
these methods (κ = 1). 
 
Figure 4. Strong linear correlation between PHH3 MI and PHH3 MI LP 
(correlation coefficient, r = 0.999; regression coefficient R
2
 = 0.999; P = 
0.001). 
22 
7. PHH3 outperformed Ki-67 LI as a prognostic indicator  
Despite the short follow up time (median 31 months), PHH3 was significantly 
associated with recurrence free survival by Log-rank test (Table 6, P = 0.006) 
while Ki-67 LI failed to be a prognostic indicator (P = 0.053).  All variables 
were evaluated for COX-multivariate regression, however neither Ki-67 LI 
nor PHH3 was a significant factor. Only the number of metastatic lymph 
nodes was shown to be of significance (P = 0.005).  
 
Figure 5. Recurrence-free survival in 218 patients for PHH3 low and high 
groups (dashed line ≤ 0.6687; solid line > 0.6687). Higher PHH3 values was 
significantly associated with worse outcome. 
23 
Table 6. Log rank (Mantel-Cox) shows significant association of low PHH3 
with recurrence free survival 
Parameters 
Total 
number/recurrence 
Disease-free survival 
Mean survival (95% CI) 
months 
P 
PHH3    
  Low 174/4 82.19 (66.32-98.05) 0.006 
  High 46/4 42.15 (40.42-43.88)  
Ki-67    
  Low 179/5 81.90 (66.62-97.18) 0.053 
  High 41/3 40.46 (38.69-42.23)  
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IV. Discussion 
Between the two proliferation markers, PHH3 is specific for mitosis in 
comparison to Ki-67. This was evident from the significant difference in 
staining percentage between the two. As evidenced by the positive linear 
relationship, the two markers proved to be related in their expressions, 
recapitulating the idea that both PHH3 and Ki-67 to some degree have an 
overlap in quantification of proliferative activity. 
The use of Ki-67 LI as representation of proliferation has long been 
under contention amongst experts, mainly due its lack of reproducibility. 
Arguably the important reason for this lack of reproducibility is due to tumor 
heterogeneity.
17
 In selection of different fields amongst raters will inevitably 
result in different scores for the same tumor. There is also the problem of lack 
of a consensus on the method of scoring. Some advocate the selective use of 
hot-spots in assessment of Ki-67,
11,17
 while others are in favor of taking the 
average of the advancing edge.
18
 In the recommendation published by the 
international Ki-67 in breast cancer working group in 2011, the method of 
overall average of the tumor, including areas of the hot spots was advocated 
for consistency among raters. Yet even with these recommendations, 
reproducibility and agreement amongst raters is a problem reported 
consistently.
17
 In the study assessing the reproducibility of Ki-67 amongst 
institutions and pathologists, there were 32% patients misclassified in terms of 
25 
low versus high Ki-67 levels, when two laboratories were compared.
19
 
Another study reported high interobserver variabilities amongst 15 
pathologists who each assessed three breast carcinoma cases (κ = 0.04-0.14).20 
In the present study, the inter-rater agreement on microscopic estimates for 
PHH3 was 0.996 in ICC, which is better than those reported for Ki-67(ICC 
0.92, 95% CI: 0.88–0.96).21 For the low κ statistic, this was most likely due to 
the small number of cases (31) assessed through pair-wise comparison in this 
study. Kappa statistics is likely to improve with more cases to fairly evaluate 
the reproducibility of PHH3. Cui et al reported that the inter-rater agreement 
for PHH3 for 97 invasive breast cancer cases, the κ statistics amongst three 
pathologists were 0.87, 0.79, 0.76, demonstrating good and reliable 
concordance. Enumeration of PHH3 on taken photographs, the κ statistics was 
0.711, which was a significant improvement from the microscopic 
evaluation.
10
 
 PHH3 also demonstrated better sensitivity for detecting mitosis than 
H-E mitotic index evaluation. This was evidenced by the up-graded 
tendencies through PHH3 enumeration. Low power assessments were also 
well correlated with those of high power field enumerations, therefore 
evidencing that mitotically active areas can be identified by low power, 
facilitating in accurate measurement of mitosis. Another similar tumor that 
also relies on mitosis for grading, is meningioma and studies demonstrated 
that those qualities of PHH3 for identification of mitotically active areas was 
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valuable in rapid, reliable grading of meningiomas.
22,23
 
 In evaluable for recurrence-free survival, PHH3 proved to be a better 
prognostic marker than Ki-67. Gerring et al. had already published that PHH3 
out-performed Ki-67 in prognostic value through multivariate Cox-
regression.
3
 However this study had been conducted with TMA samples, 
therefore in disagreement of the actual practice of assessing Ki-67 and PHH3. 
Our study is better representative of the actual practice because of our 
assessment of surgical slides for analysis. 
 The limitation of this study was the short follow up time with a mean 
follow up of 31 months and the longest time recorded at 93 months. Gerring 
et al
3
 had reported on the prognostic value after following up on patients for 
the maximum length of 191 months with a median follow up of 85months. 
Due to the long duration of follow up, they were able to accumulate enough 
data of patient survival (a total of 54 deaths out of a total of 108 patients).
3
 
Their data had allowed for a significant value of PHH3 on multivariate cox 
regression, proving that PHH3 to be a better prognostic marker than Ki-67. 
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V. Conclusion 
In this study, we present a possibility to utilize PHH3 as reinforcing 
weaknesses of Ki-67. PHH3 is a marker specific for mitosis that is expressed 
in all stages of mitosis. It therefore reliably discriminates actually 
proliferating cells from mimickers that are difficult or impossible to 
discriminate on H-E mitotic index or Ki-67 LI. It also has an advantage in 
heterogeneous tumors that identifies mitotically active areas allowing for a 
good reproducibility amongst raters. Despite the problems of reproducibility 
and no better known alternative, Ki-67 LI has long been the mode of 
evaluation of breast cancer proliferative activity in many pathology centers. 
The findings of our study advocate the routine use of PHH3 in diagnostics to 
reinforce the weaknesses of Ki-67. 
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ABSTRACT (IN KOREAN) 
 
Invasive breast cancer의 증식력을 평가하는 도구로서 
Phosphohistone H3 의 유용성:  
Ki-67와의 비교를 중심으로  
 
<지도교수 구자승> 
연세대학교 대학원 의학과 
김 지 예 
 
Ki-67은 종양의 증식력을 평가하는데 있어 널리 사용하는 
표지자로서 유방암에서 환자의 항암치료의 반응 정도를 
예측하는 인자로서 사용되고 있다.  그러나 Ki-67은 
증식력을 반영하는데 있어 비특이적이고 재현성이 낮다는 
문제가 있다. 대조적으로 Phosphohistone H3 (PHH3)는 
증식력으로 정의되는 유사분열에 대해 특이적이고 재현성 
높은 표지자로 알려져 있다. 본 연구는 유방암의 증식력을 
평가하는데 있어 두 표지자의 유용성을 비교하였다.  
연구방법: 2012년도부터 2013년 까지 유방암으로 수술한 
환자의 FFPE 중 가장 대표성 있는 단면에 Ki-67과 PHH3의 
IHC 염색을 하여 비교하였다.  
결과: Ki-67과 PHH3은 서로간의 양의 상관관계가 있었다. 
PHH3의 재현성을 확인하기 위해 두 가지 방법을 통해 두 
명의 평가자 간의 평가 일치도를 확인하였다. 첫 번째 방법은, 
33 
동일 슬라이드를 현미경에서 관찰하여 평가하였고, 두 번째 
방법은 동일 영역의 사진을 평가하게 하였다. 두 방법 모두 
거의 완벽한 급내 상관 계수(0.996, 0.977)를 나타냈다. 
PHH3로서 저배율에서 유사분열이 가장 많은 영역을 발견할 
수 있는지 알아보기 위해 PHH3를 저배율로 평가한 수치와 
고배율로 10개의 영역을 평가한 수치를 비교하였을 때 높은 
상관성을 보였다(r = 0.999). 마지막으로, PHH3는 
recurrence-free survival(P = 0.006) 와 유의한 관련성이 
있었으나, Ki-67 은 그렇지 않았다(P = 0.053).  
결론: Ki-67의 낮은 특이도와 재현성의 문제를 보완하기 위해 
PHH3를 보조적으로 사용하면 유방암의 증식력을 보다 
정확하게 평가할 수 있다. 
 
 
 
 
 
 
 
 
 
 
 
핵심되는 말: Ki-67, PHH3, 유방암, 증식력, 신뢰도 
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